Eizen Joshua M's Form 4 filing
AN2 Therapeutics, Inc. (ANTX) · filed Jan 7, 2026
- Accession no.
- 0001193125-26-006763
- Filed
- Jan 7, 2026
- Trade date
- Jan 5-6, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $24.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Eizen Joshua MCIK 0001949621 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 5, 2026 | Common Stock | SSaleDisposed | −17,923 | $1.00F2 | −$17,923 | 159,430 | Direct | |
| Jan 6, 2026 | Common Stock | SSaleDisposed | −6,931 | $1.01 | −$7,000.31 | 152,499 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $1.001 to $1.003 per share. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
Remarks
Chief Operating Officer and Chief Legal Officer